In autumn 2018, CMAB Biopharma AG opened its International Office in Basel. Basel is the first location for CMAB outside of China and enables deployment of their world class monoclonal antibody and biologics development and manufacturing services internationally.
“We are delighted with our Basel hub, which gives us the opportunity to become a global contract development and manufacturing organization,” says Michael Frizberg, President CMAB Biopharma International. “The expansion to Europe reflects our rate of growth and scope of ambition.” CMAB took the big step to Basel just over one year after founding their company in June 2017 and it quickly follows the recent opening of their current good manufacturing site in Suzhou, China.
Barry Shortt, Senior Director at CMAB Biopharma in Basel, appreciates the choice of location: “CMAB identified Basel as one of the most active and progressive biotechnology regions in the world that allows us to directly partner, collaborate and serve our European and International clients.”
CMAB Biopharma is a new, dedicated full-service contract development and manufacturing organization (CDMO) designed to provide an integrated process development and manufacturing service for biologic products to global clients.
CMAB Biopharma completed its series A financing of 38 million USD in January 2018 and secured a series B financing of 34 million USD in April 2018. The 10,500 sqm facility will generate pre-clinical and early-stage clinical products, following global quality standards (NMPA, 21 CFR, Eudralex, WHO, harmonized PIC/S and ICH standards).
Find further information at www.cmabbio.com or contact CMAB through firstname.lastname@example.org